Thariat J, Vignot S, Bensadoun R-J, Mornex F
Département de radiothérapie oncologique, centre Antoine-Lacassagne, institut universitaire de la face et du cou, Nice, France.
Cancer Radiother. 2012 Sep;16(5-6):325-9. doi: 10.1016/j.canrad.2012.04.005. Epub 2012 Jul 10.
Systemic treatments rarely allow durable disease control at a metastatic stage. However, distinct metastatic profiles should be considered: from an oligometastatic state (one to five metastases) to disseminated metastases. Biomolecular mechanisms of metastatic spread and patterns of presentation and care were studied. A review of the literature focusing on local ablative treatments of oligometastases was performed. Improvement of local treatments, including surgical ablation, radiofrequency and irradiation (mostly with stereotactic radiotherapy) allow for metastatic control rates at treated sites of over 70% and increased survival with preserved quality of life. Improvements of ablative local treatments have dramatically modified the management of the oligometastatic disease. Metastatic disease may become in rare occasions a chronic disease, with some patients experiencing prolonged remission or even cure, provided proper selection of patients for local aggressive treatments using optimal criteria and scores that remains to be defined.
全身治疗在转移性阶段很少能实现持久的疾病控制。然而,应考虑不同的转移特征:从寡转移状态(1至5个转移灶)到播散性转移。对转移扩散的生物分子机制以及表现和治疗模式进行了研究。对聚焦于寡转移灶局部消融治疗的文献进行了综述。包括手术消融、射频和放疗(主要是立体定向放疗)在内的局部治疗的改进,使治疗部位的转移控制率超过70%,并提高了生存率,同时保持了生活质量。消融性局部治疗的改进极大地改变了寡转移疾病的管理。在极少数情况下,转移性疾病可能成为一种慢性病,只要使用有待确定的最佳标准和评分,为局部积极治疗正确选择患者,一些患者就会经历长期缓解甚至治愈。